Join our daily newsletter At The Bell to receive exclusive market insights
- Medical company Exopharm (EX1) has announced a number of changes to its board following the resignation of David Parker
- David was a Board Director and has departed the company after a tenure of 28 months
- He will be replaced by Elizabeth McGregor, who will take on the role as Board Director and Company Secretary
- Exopharm explains that Elizabeth comes from the Automatic Group and works for a number of ASX-listed entities
- Shares in EX1 are trading down 6.08 per cent at 54.5 cents each
Exopharm (EX1) has announced a number of changes to its board, following the resignation of David Parker.
David previously held the position of Director of the EX1 Board and departs the medical company after a tenure of 28 months.
He will be replaced by Elizabeth McGregor, who will take on the role of both Board Director and Company Secretary.
The company explains that Elizabeth will bring vast experience to the role, having worked for several ASX-listed entities as well as the Automatic Group.
In the meantime, Sinead Teague has resigned as Exopharm’s current Company Secretary ahead of her planned departure from the Automic Group.
Commenting on the changes, EX1 Founder and CEO Ian Dixon said he’s sad to see David leave.
“David really jumped into Exopharm in early 2018 and helped me prepare for the IPO and dealing with so much of the compliance and regulatory issues at that
time,” he said.
“After the IPO, David continued to support the company and the executive team in many ways including as Company Secretary. David remains a substantial shareholder and friend of the company and we wish him well on his next journey,” he added.
Shares in EX1 are trading down 6.08 per cent at 54.5 cents each at the close of trade on Tuesday.
